Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Baxter
Colorcon
Medtronic

Last Updated: September 24, 2022

Details for Patent: 8,932,610


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,932,610 protect, and when does it expire?

Patent 8,932,610 protects OTOVEL and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 8,932,610
Title:Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
Abstract: A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers.
Inventor(s): Ruiz I Pol; Jaume (Esplugues de Llobregat, ES), Izquierdo Torres; Francisca (Esplugues de Llobregat, ES)
Assignee: Laboratorios Salvat, S.A. (Esplugues de Llobregat (Barcelona), ES)
Application Number:12/730,681
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use; Dosage form;

Drugs Protected by US Patent 8,932,610

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Laboratorios Salvat OTOVEL ciprofloxacin hydrochloride; fluocinolone acetonide SOLUTION/DROPS;OTIC 208251-001 Apr 29, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF ACUTE OTITIS MEDIA See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,932,610

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10155005Mar 1, 2010

International Family Members for US Patent 8,932,610

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 080368 See Plans and Pricing
Australia 2011223095 See Plans and Pricing
Brazil 112012021638 See Plans and Pricing
Canada 2790652 See Plans and Pricing
China 102811741 See Plans and Pricing
Denmark 2366408 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Colorcon
Medtronic
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.